Phase II study of T-Bren (BL-M07D1) monotherapy or in combination with pertuzumab in patients with treatment-naïve HER2-positive unresectable locally advanced or metastatic (LA/M) breast cancer.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, The First People's Hospital of Zhaoqing, Harbin Medical University, Wuhan Union Hospital, Huazhong University of Science and Technology, Anyang Tumor Hospital, Shandong First Medical University, First Hospital of Jilin University, Hainan Medical University, Fujian Provincial Cancer Hospital, Jilin Province Tumor Hospital, First Affiliated Hospital of Henan University of Science and Technology, Hainan General Hospital, Sichuan Baili Pharmaceutical Co., Ltd. (China)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162537077
Cites:
Cited by:
Related to: